NCT03057457View on ClinicalTrials.gov

The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

UnknownOBSERVATIONAL
Enrollment

530

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2018

Conditions
Kidney Injury
Interventions
DEVICE

NGAL Test

The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.

Trial Locations (2)

80218

RECRUITING

Colorado Kidney Care, Denver

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

BioPorto Diagnostics

INDUSTRY

NCT03057457 - The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population | Biotech Hunter | Biotech Hunter